Linxens site in France receives ISO 13485:2016 certification
Linxens has announced that its plant in Mantes-la-Jolie (Yvelines, France) has received the ISO 13485: 2016 certification, for the design, industrialisation and manufacture of sub-components for medical devices.
This will accelerate the group's development in the health sector, with the prospect of new jobs being created in Mantes-la-Jolie, France.
With seven production sites worldwide, Linxens is a global specialist in the manufacture of microconnectors and RFID antennas for smart cards. Thanks to its Research & Development potential and its exceptional industrial capacity, the group has established itself over the last years as a key player in many markets, notably banking and telecoms.
Today, Linxens is accelerating its growth in high-potential areas, such as connected objects and healthcare. As a tangible sign of this approach, the group obtained, in February 2022, ISO 13485: 2016 certification for its Mantes-la-Jolie plant in France. The site thus becomes the first in the group to receive this certification, which enables it to manufacture microcircuits on flexible substrates for medical device manufacturers.
"The medical sector is currently undergoing a real transformation, with the arrival of new technologies that can be used in a number of ways: to combat medical deserts via telemedicine booths, to promote the early detection of illnesses with individual medical devices, and to shorten hospital stays through remote monitoring
“With its skilled and committed teams and its industrial capabilities combining quality and volume, Linxens aims to foster and accelerate this transformation, enabling patients to benefit from better care, without increasing the costs to the community.
“The ISO 13485 certification obtained by the Mantes-la-Jolie site is a key step in our development strategy towards products for the healthcare market," explained Arnaud Brunetière, Chief Operating Officer, Linxens.
Technologies for the global medical sector
Linxens has seven production sites, and the certification of the Mantes-la-Jolie site in France is also an assurance for its development. The Mantes-la-Jolie site was chosen to develop the group's medical activity, in particular because of the R&D capacity on site, with teams of 35 engineers and technicians that will undoubtedly grow in the coming years.
"Our site in Yvelines is the focus of numerous investments. Its R&D center enables us to develop new products and services - as is the case today with the new ISO 13485 certification for healthcare - and to support innovation in our traditional markets, such as the banking sector. To support this growth, we continue to recruit a variety of profiles, including experienced technicians, operators and R&D engineers." concluded Cuong H. Duong, CEO of Linxens.